Pentacyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 514/280)
-
Patent number: 8815306Abstract: Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed.Type: GrantFiled: March 14, 2008Date of Patent: August 26, 2014Assignee: Metaproteomics, LLCInventors: Matthew L. Tripp, Veera Konda, Anu Desai, Amy J. Hall, Jeffrey S. Bland
-
Publication number: 20140213604Abstract: The subject invention concerns a method of inhibiting respiratory syncytial virus (RSV) infection in a patient by decreasing the endogenous protein kinase C (PKC) activity within the patient. Preferably, the preventative and therapeutic methods of the present invention involve administration of a PKC inhibitor. The present inventor has determined that decreasing normal endogenous PKC activity is inhibitory to RSV infection of human cells. The subject invention also pertains to pharmaceutical compositions containing a PKC inhibitor and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 18, 2014Publication date: July 31, 2014Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: SHYAM S. MOHAPATRA, HOMERO GABRIEL VERGARA
-
Publication number: 20140200234Abstract: The present invention involves the use of 2,4-disulfonyl phenyl tert-butyl nitrone (2,4-ds-PBN) in the treatment and prevention of gliomas. The 2,4-ds-PBN may be used alone or combined with other traditional chemo- and radiotherapies and surgery, to treat or prevent glioma occurrence, recurrence, spread, growth, metastasis, or vascularization.Type: ApplicationFiled: January 21, 2014Publication date: July 17, 2014Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Rheal A. TOWNER, Robert A. FLOYD
-
Publication number: 20140200226Abstract: Novel compositions and methods for the treatment and prevention of malaria are disclosed herein.Type: ApplicationFiled: December 12, 2013Publication date: July 17, 2014Applicants: Florida Atlantic University, University of Central Florida Research Foundation, Inc.Inventors: Debopam Chakrabarti, Amy Wright
-
Publication number: 20140178447Abstract: Disclosed herein are methods and compositions for rendering medical devices and other surfaces biofilm resistant by the use of a coating composition comprising a combination of one or more antimicrobial agent, one or more anti-inflammatory agent, optionally a releasing agent, optionally decandediol, and a lubricious matrix system comprising a biomedical polymer. In certain embodiments said coating composition is adhered to the device or surface by a coating comprising urethane and silicone adhesives.Type: ApplicationFiled: February 28, 2014Publication date: June 26, 2014Inventors: Shanta M. Modak, Ronald Citron, Santoshkumar Dongre, Nayana Baiju, Arnab Kumar Ghosh
-
Patent number: 8741917Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.Type: GrantFiled: January 15, 2010Date of Patent: June 3, 2014Assignee: Rutgers, The State University of New JerseyInventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul
-
Publication number: 20140148398Abstract: Compounds useful for the treatment of giardiasis are described.Type: ApplicationFiled: October 12, 2011Publication date: May 29, 2014Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Service, UNIVERSITY OF MARYLAND, COLLEGE PARKInventors: Wei Zheng, Catherine Chen, Juan Jose Marugan, Noel Southall, Christopher P. Austin, Andrey Galkin, Liudmila Kulakova, Osnat Herzberg
-
Patent number: 8710071Abstract: The present technology relates to compounds of Formulas (V) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated protein kinase.Type: GrantFiled: December 22, 2009Date of Patent: April 29, 2014Assignee: CVI Pharmaceuticals LimitedInventors: Haiyan Liu, Gaoping Li, Junbo Wang, Jingwen Liu
-
Publication number: 20140113879Abstract: The present invention relates to the field of polymer chemistry and more particularly to multiblock copolymers and micelles comprising the same. Compositions herein are useful for drug-delivery applications.Type: ApplicationFiled: September 16, 2013Publication date: April 24, 2014Applicant: Intezyne Technologies, Inc.Inventors: Adam Carie, Kevin Sill
-
Patent number: 8697743Abstract: The present invention is directed to antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs and the preparation of nanometer-sized camptothecin prodrugs. Methods of synthesizing the antioxidant derivatives of camptothecin and antioxidant derivatives of camptothecin analogs, spontaneous emulsification or nanoprecipitation thereof to produce antioxidant camptothecin nanosphere prodrugs and their use in treating cancerous diseases are also provided. A further aspect of this invention is the use of these antioxidant camptothecin nanosphere prodrugs for the preparation of delivery devices of other pharmaceuticals and/or drugs. Additionally, methods of treating cancer with the camptothecin and antioxidant derivatives of camptothecin analogs, and nanometer-sized camptothecin prodrugs are also provided.Type: GrantFiled: May 24, 2011Date of Patent: April 15, 2014Assignee: Cedars-Sinai Medical CenterInventors: John S. Yu, Bong Seop Lee
-
Patent number: 8686146Abstract: The invention described herein pertains to substituted azaindenoisoquinoline compounds, in particular 7-, 8-, 9-, and 10-azaindenoisoquinoline compounds, which are inhibitors of topoisomerase I, processes and intermediates for their syntheses, pharmaceutical compositions of the compounds, and methods of using them in the treatment of cancer.Type: GrantFiled: July 13, 2012Date of Patent: April 1, 2014Assignee: Purdue Research FoundationInventors: Mark S. Cushman, Evgeny A. Kiselev, Andrew E. Morrell
-
Publication number: 20140088130Abstract: The present invention relates to a novel hexahydrodibenzo[a,g]quinoline compound represented by general formula (I) and its derivatives, enantiomer, diastereoisomer, raceme and mixtures thereof, as well as pharmaceutically acceptable salts thereof. The present invention further relates to a method for preparing the compound, and the compound has good prevention and treatment effect on neurological diseases, especially diseases associated with dopamine receptor and 5-hydroxytryptamine receptor. The bioactivity experiment demonstrates that, the compound is expected to be developed into a novel and potent chemical entity for treating diseases associated with dopamine receptor and 5-hydroxytryptamine receptor, especially schizophrenia, Parkinson's disease, drug addiction, migraine and so on.Type: ApplicationFiled: November 27, 2013Publication date: March 27, 2014Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCESInventors: Hong LIU, Xin XIE, Xuechu ZHEN, Haifeng SUN, Jing LI, Liyuan ZHU, Zeng LI, Ying CHEN, Hualiang JIANG, Kaixian CHEN
-
Patent number: 8653095Abstract: The present invention provides new chemical compositions with desirable biological activity and toxicity profiles for the enhanced treatment of malaria.Type: GrantFiled: July 18, 2011Date of Patent: February 18, 2014Assignee: Radix Pharmaceuticals, Inc.Inventor: Shuren Zhu
-
Patent number: 8648090Abstract: Indole alkaloid derivatives having an opioid receptor agonistic effect, their synthesis, and therapeutic compositions containing these derivatives, and methods of treating conditions with these compounds and therapeutic compositions, are provided.Type: GrantFiled: July 16, 2012Date of Patent: February 11, 2014Assignees: National University Corporation Chiba University, Josai University CorporationInventors: Hiromitsu Takayama, Mariko Kitajima, Kenjiro Matsumoto, Syunji Horie
-
Publication number: 20140023653Abstract: The present invention provides compositions comprising a compound of Formula I, and salts, hydrates, and isomers thereof. Methods of promoting bone formation and/or bone growth, treating renal disease, and treating cancer in a subject in need thereof, by administering to the subject a therapeutically effective amount of a compound of Formula I, are also provided. Medical devices comprising a compound of Formula I are also provided.Type: ApplicationFiled: July 16, 2013Publication date: January 23, 2014Inventors: Debra Ellies, Ferris Scott Kimball
-
Publication number: 20140018382Abstract: A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day. In homeopathic use, the reserpine may be administered in the form of a homeopathic dilution, preferably as a 12 C homeopathic dilution of reserpine.Type: ApplicationFiled: May 14, 2013Publication date: January 16, 2014Applicant: MedDEV, Inc.Inventor: Elaine A. DeLack
-
Publication number: 20140011830Abstract: The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy, known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.Type: ApplicationFiled: July 6, 2012Publication date: January 9, 2014Inventor: Robert Lewis Steele
-
Publication number: 20140011829Abstract: The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual.Type: ApplicationFiled: July 6, 2012Publication date: January 9, 2014Inventors: Robert Lewis Steele, Anthony Fedele Musso
-
Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
Patent number: 8618123Abstract: Disclosed are novel gamma secretase inhibitors of the formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, wherein L1, n, X, Ar, Y, Z, Q, and Q1 are as defined herein. Also disclosed are methods for inhibiting gamma secretase, methods for treating Alzheimer's disease, methods of treating one or more neurodegenerative diseases, and methods of inhibiting the deposition of amyloid protein (e.g., amyloid beta protein) in, on or around neurological tissue (e.g., the brain) using the compounds of formula 1.0.Type: GrantFiled: July 15, 2008Date of Patent: December 31, 2013Assignee: Merck Sharp & Dohme Corp.Inventors: Thavalakulamgara K. Sasikumar, Duane A. Burnett, Theodros Asberom, Wen-Lian Wu, Hongmei Li, Ruo Xu, Hubert B. Josien -
Publication number: 20130345249Abstract: The invention encompasses pharmaceutical formulations for the prevention and treatment of Wolbachia-related disease wherein the formulations comprise a compound previously unknown and unused for such a purpose, the compound being one or more of: Pararosaniline Pamoate, Pyrvinium Pamoate, Clofoctol, and Isoreserpine, derivatives, metabolites, precursors, pro-drugs and variants thereof.Type: ApplicationFiled: January 13, 2012Publication date: December 26, 2013Applicant: The Regents of the University of CaliforniaInventors: Alain Debec, Laura Serbus, Frederic Landmann, William Sullivan
-
Publication number: 20130345164Abstract: This invention concerns methods of identifying treatments for treating various disorders and related computer products and systems. Also disclosed are methods for treating cellular proliferative disorders and use of compounds identified for such treatment.Type: ApplicationFiled: April 21, 2011Publication date: December 26, 2013Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventors: Alexei Vazquez, Darren Carpizo, Arnold Levine
-
Publication number: 20130317018Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.Type: ApplicationFiled: November 9, 2011Publication date: November 28, 2013Inventors: Benjamin David Philpot, Mark John Zylka, Bryan Leo Roth, John Arthur Allen, Hsien-Sung Huang
-
Publication number: 20130310411Abstract: The present invention relates to novel acridine derivatives of formula (I), or pharmaceutically acceptable salts thereof, which are inhibitors of the telomerase enzyme function. These compounds are useful for the treatment cellular proliferation disorders, such as cancer.Type: ApplicationFiled: September 29, 2011Publication date: November 21, 2013Applicant: PHARMINOX LIMITEDInventors: Marc Geoffery Hummersone, David Cousin, Mark Frigerio
-
Publication number: 20130302264Abstract: Provided are indole alkaloid compounds of formula I, for example, pubescine, and the use of such compounds and compositions thereof to promote (e.g., enhance) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, pubescine, and the use of such a plant extract to promote (e.g., enhance) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.Type: ApplicationFiled: November 16, 2011Publication date: November 14, 2013Applicant: NEW YORK UNIVERSITYInventors: Seth J. Orlow, Li Ni Komatsu
-
Patent number: 8569327Abstract: A novel compound having an excellent NF?B inhibitory effect is provided. Specifically disclosed is a compound represented by the following formula (1) or a salt thereof: wherein, R1 represents a hydrogen atom, a lower alkyl group, or the like; R2 represents a hydrogen atom, a lower alkyl group, a halogen atom, or the like; R3 represents a hydrogen atom, a lower alkyl group, a hydroxyl group, or a halogen atom; R4 represents a hydrogen atom or a lower alkyloxy group; R5 represents a hydrogen atom, a lower alkyloxy group, a halogen atom, a hydroxyl group, or a methylenedioxy group formed together with R6 or an isopropylidenedioxy group formed together with R6; R6 represents a hydrogen atom, a lower alkyloxy group, or a methylenedioxy group formed together with R5 or an isopropylidenedioxy group formed together with R5; R7 represents a hydrogen atom or a lower alkyl group; and R8 represents a hydrogen atom, a hydroxyl group, an amino group, a lower alkylcarbonyloxy group, or a halogen atom.Type: GrantFiled: October 23, 2009Date of Patent: October 29, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Takashi Ikeda, Seigo Sawada, Takashi Yaegashi, Takeshi Matsuzaki, Shusuke Hashimoto, Ryuta Yamazaki
-
Publication number: 20130281478Abstract: The invention relates to a combination of syrosingopine and a mitochondrial inhibitor, e.g. metformin or oligomycin, and the use of the combination of syrosingopine and a mitochondrial inhibitor for the treatment of cancer and for achieving immunosuppression. The invention also relates to a fluorescence-based method for predicting syrosingopine sensitivity of a cancer cell.Type: ApplicationFiled: January 9, 2012Publication date: October 24, 2013Inventors: Don Benjamin, Marco Colombi, Michael Hall, Christoph Moroni
-
Publication number: 20130261142Abstract: The present invention discloses compounds for the treatment of cancer and its application. These compounds comprises one of the following compound: Ammonium pyrrolidinedithiocarbamate Bay 11-7085 BIO Brefeldin A (+)-Butaclamol Calcimycin Calmidazoliur chloride Chelerythrine chloride CK2 Inhibitor 2 CGP-74514A hydrochloride CGS-12066A meleate Dequalinium dichloride Dihydroouabain Diphenyleneiodonium chloride Emetine dihydrochloride hydrate GR 127935 hydrochloride Nifedipine 6-Nitroso-1,2-benzopyrone Palmitoyl-DL-Carnitine chloride Parthenolide PD 169316 1,10-Phenanthroline monohydrate 4-Phenyl-3-furoxancarbonitrile Prazosin hydrochloride Protoporphyrin IX disodium Quinacrine dihydrochloride Quabain Retinoic acid p-hydroxyanilide Rottlerin Sanguinarine chloride Tetraethylthium disulfide and SU 9516.Type: ApplicationFiled: December 15, 2010Publication date: October 3, 2013Inventor: Hung-Cheng Lai
-
Publication number: 20130237557Abstract: The present invention derives from the finding that increased levels of alpha 2a adrenergic receptors (ADRA2a) are associated with chronic liver disease and that by decreasing ADRA2a levels in vivo, a number of symptoms and consequences of chronic liver disease may be reduced. Accordingly, the invention provides ADRA2a antagonists for use in a method of treating an individual suffering from liver disease.Type: ApplicationFiled: August 12, 2011Publication date: September 12, 2013Applicant: UCL BUSINESS PLCInventors: Rajeshwar P. Mookerjee, Vikram Sharma, Rajiv Jalan
-
Publication number: 20130237556Abstract: The present invention is directed to method of preventing or treating neural disease or inhibiting accumulation of ?-amyloid plaques in a subject by administering an effective dosage to the subject an agent (berberine) which inhibits the accumulation of ?-amyloid- plaque, phospho-amyloid precursor protein (p-APP) and tau hyperphosphorylation in a mammalian brain.Type: ApplicationFiled: March 12, 2013Publication date: September 12, 2013Applicant: HONG KONG BAPTIST UNIVERSITYInventors: Min LI, Siva Sundara Kumar DURAIRAJAN, Liangfeng LIU, Jiahong LU
-
Patent number: 8524214Abstract: Polyal-Drug conjugates comprising a variable rate-releasing linker are described along with methods of making such conjugates. Uses for such Polyal-Drug conjugates is also described.Type: GrantFiled: May 27, 2010Date of Patent: September 3, 2013Assignee: Mersana Therapeutics, Inc.Inventors: Aleksandr Yurkovetskiy, Mao Yin, Gui Liu, Laura C. Akullian, John J. Kane, Cheri A. Stevenson, Charles E. Hammond, Russell C. Petter, John H. Van Duzer, Timothy B. Lowinger
-
Patent number: 8518961Abstract: The present invention relates to novel pharmaceutical compositions in which the active agent is a topoisomerase I inhibitor, in particular a camptothecin derivative, that is useful for the treatment and prevention of proliferative diseases including cancer.Type: GrantFiled: November 17, 2005Date of Patent: August 27, 2013Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.Inventor: Isabel Ottinger
-
Patent number: 8507477Abstract: Compounds of Formula (I): (where variables R1A, R1B, R2, R3, R4, A, and Z are as defined herein) which are useful as antagonists of CGRP receptors, and useful in the treatment or prevention of diseases in which CGRP receptors are involved, such as headache, and in particular migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP receptors are involved.Type: GrantFiled: August 14, 2009Date of Patent: August 13, 2013Assignee: Merck, Sharp & Dohme, Corp.Inventors: Michael R. Wood, Ian M. Bell, June J. Kim, Harold G. Selnick, Craig A. Stump
-
Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
Patent number: 8501167Abstract: Provided herein are compositions and methods for targeted ablation of mutational escape in the face of cancer therapeutic agents. Compositions comprising the yeast-based vehicles are used in combination with other cancer therapeutic agents.Type: GrantFiled: January 17, 2008Date of Patent: August 6, 2013Assignee: GlobeImmune, Inc.Inventors: David Apelian, Alex Franzusoff, Timothy C. Rodell -
Publication number: 20130195751Abstract: Provided are a self-assembled conjugate of a host molecule containing compound and a guest molecule containing compound, a delivery composition of a bioactive material comprising the self-assembled conjugate and a bioactive material to be delivered, and a composition for tissue engineering containing the self-assembled conjugate and a cell.Type: ApplicationFiled: January 31, 2012Publication date: August 1, 2013Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Sei Kwang HAHN, Kimoon KIM, Hyuntae JUNG, Jeong-A YANG, Kyeng Min PARK
-
Patent number: 8486957Abstract: A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described.Type: GrantFiled: February 24, 2010Date of Patent: July 16, 2013Assignee: Wake Forest University Health SciencesInventors: Freddie R. Salsbury, Jr., Karin D. Scarpinato, S. Bruce King
-
Patent number: 8481558Abstract: Isolated and purified chemokine peptides, variants, and derivatives thereof, as well as chemokine peptide analogs, are provided.Type: GrantFiled: June 7, 2011Date of Patent: July 9, 2013Assignee: Cambridge Enterprise LimitedInventors: David J. Grainger, Lauren M Tatalick
-
Publication number: 20130150429Abstract: Cells expressingHsp27 exhibit reduced levels of p27kip1. Accordingly, a method for treatment of cancer using hsp27 inhibition that includes a preliminary test to ascertain the status of the p27kip1 in the target cells. In this test, a sample of cancerous tissue from the patient from the patient (including a human patient) and evaluated to determine an expression of level of functional p27kip1. In the case where the expression level of p27kip1 is below a threshold level, a therapeutic composition comprising as an active agent a composition effective to inhibit the expression or activity of hsp27 in administered to the patient.Type: ApplicationFiled: December 6, 2012Publication date: June 13, 2013Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventor: The University of British Columbia
-
Publication number: 20130131006Abstract: The present invention relates to a method for inhibiting the induction of cell death by inhibiting the synthesis or secretion of AGE-albumin in cells of the mononuclear phagocyte system, to an AGE-albumin synthesis inhibitor, and to a pharmaceutical composition comprising the AGE-albumin synthesis inhibitor for preventing or treating degenerative disease and autoimmune disease. The AGE-albumin of the present invention is synthesized and secreted in human microglia or human macrophages in an Alzheimer's model, stroke model, Parkinson's disease model and rheumatoid arthritis model. The AGE-albumin synthesis and secretion are caused by oxidative stress. The expression of RAGE increases in first-order human neurons or cartilage cells to which AGE-albumin is administered, whereupon a MAPK signaling pathway is activated and the expression of Bax increases to induce an increase in calcium in mitochondria, thus finally inducing cell death.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Applicant: Gachon University of Industry-Academic Cooperation FoundationInventors: Bong Hee Lee, Kyung Hee Byun
-
Patent number: 8440685Abstract: A method for treatment of the symptoms of neurologic dysfunctions, including major depression, an autism spectrum disorder (ASD), and schizophrenia. The patient is administered an amount of a compound that increases the catalytic activity of MAO-A. The effective compound is preferably reserpine, administered in a dosage of less than about 0.03 mg per day. The reserpine may be administered topically or transdermally at a dosage in the range from about 0.002 mg per day to about 0.02 mg per day.Type: GrantFiled: January 12, 2010Date of Patent: May 14, 2013Assignee: MedDEV, Inc.Inventor: Elaine A. DeLack
-
Publication number: 20130115202Abstract: This disclosure pertains to methods of treating a neuro-inflammation disorder in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid, or a structurally related analogue, olive kernel extract, hydroxytyrosol, and berberine, and, optionally, one or more ingredients selected from the group consisting of a sulfated proteoglycan, oleocanthal, a CRH antagonist, S adenosylmethionine, a histamine 1 receptor antagonist, a histamine 3 receptor agonist, emu oil, oregano oil, grape seed oil, aloe extract, biotin, and selenium. Certain of the present compositions are useful in protecting against or treating neuro-inflammation associated with allergies, Alzheimer's disease (AD), atherosclerosis, asthma, Autistic Spectrum Disorders (ASD).Type: ApplicationFiled: December 20, 2012Publication date: May 9, 2013Applicant: THETA BIOMEDICAL CONSULTING & DEVELOPMENT CO., INCInventor: Theta Biomedical Consulting & Development Co., Inc
-
Patent number: 8435963Abstract: This invention provides unique and advantageous formulations and methods for weight loss.Type: GrantFiled: September 25, 2009Date of Patent: May 7, 2013Inventor: John H. Owoc
-
Bioactive composition for the treatment of the HIV/AIDS, method for manufacturing and using the same
Patent number: 8431153Abstract: The present invention is about a bioactive composition for the treatment of HIV, particularly by the removal of the most prominent HIV antigen glycoproteins. The present invention further relates to the method for making and using such composition.Type: GrantFiled: November 6, 2008Date of Patent: April 30, 2013Assignee: Celebrity Biogens, LLCInventor: Mukesh Harilal Shukla -
Publication number: 20130102625Abstract: An all-natural herbal composition and methods of preparing the same are provided. The novel Artemisinin Combination Therapy (ACT) consists of artemisinin and its derivatives and berberine, the two active substances mixed with various selected excipient compounds to form a single pill, tablet or capsule for treatment and prevention of malaria, dengue fever, yellow fever, dysentery, Lyme disease, babesiosis, progressive multifocal leukoencephalopathy, Helicobacter Pylori, and colitis, in adults and children. A tablet or pill for children is formulated to be chewable.Type: ApplicationFiled: October 25, 2012Publication date: April 25, 2013Applicant: U.S. PHYTOTHERAPY, INC.Inventor: U.S. PHYTOTHERAPY, INC.
-
Patent number: 8415348Abstract: The present invention concerns nitrogenated derivatives of narciclasine and pancratistatin of the following general formula (I) as well their pharmaceutically acceptable salts. The present invention also concerns the use of these compounds in cancer therapy as well as a method for their preparation.Type: GrantFiled: July 28, 2009Date of Patent: April 9, 2013Assignee: Pierre Fabre MedicamentInventors: Frédéric Marion, Jean-Philippe Annereau, Jacques Fahy
-
Publication number: 20130084345Abstract: The invention provides combination therapy, wherein one or more other therapeutic agents are administered with indibulin or a pharmaceutically acceptable salt thereof and the combination is synergistic. Another aspect of the invention relates to the treatment of cancer with indibulin as a single agent. Another aspect of the invention relates to dosing regimen for administration of oral dosage forms of indibulin.Type: ApplicationFiled: November 20, 2012Publication date: April 4, 2013Applicant: ZIOPHARM ONCOLOGY, INC.Inventor: Ziopharm Oncology, Inc.
-
Publication number: 20130071474Abstract: This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition.Type: ApplicationFiled: February 9, 2011Publication date: March 21, 2013Inventor: John Colman
-
Publication number: 20130072463Abstract: Disclosed is a method of treating a cancer on a mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of a compoundType: ApplicationFiled: November 12, 2012Publication date: March 21, 2013Applicant: MITOTECH SAInventor: Mitotech SA
-
Publication number: 20130072513Abstract: This invention relates to compositions and methods of combining berberine, artemisinin and loperamide or their derivatives in a therapeutic product for mammals suffering from malaria, diarrhea, travelers' diarrhea, dysentery, dengue fever, parasites, cholera and viruses by administration of a therapeutically effective amount of the composition.Type: ApplicationFiled: February 9, 2011Publication date: March 21, 2013Inventor: John Colman
-
Publication number: 20130065875Abstract: The invention provides derivatives and analogues of triazatetracyclo[7.7.0.01,13,02,7]-hexadeca-2,4,6,10,12-pentaenes, 5,7,11-triazatetracyclo[8.7.0.01,6,012,17]-heptadeca-6,8,12,14,16-pentaenes, pharmaceutical compositions comprising these compounds and methods for treatment of hepatitis C viral infections using these compounds.Type: ApplicationFiled: October 27, 2010Publication date: March 14, 2013Applicants: THE SCRIPPS RESEARCH INSTITUTE, TRUSTEES OF BOSTON UNIVERSITYInventors: John K. Snyder, Wanguo Wei, Feng Ni, Arthur Donny Strosberg, Smitha Kota, Virginia Takahashi
-
Publication number: 20130045987Abstract: Tetrahydroberberine (THB), isolated from the Chinese herb “Corydalis ambigua”, exhibits a variety of pharmacological effects, although mechanisms of action are unclear or entirely unknown. Described herein are novel methods of using tetrahydroberberine (THB), THB analogs or derivatives, tetrahydroprotoberberines (THPB). Tetrahydroberberine (THB) and analogs such as l-stepholidine (l-SPD) potently block functional KATP channels natively expressed on midbrain dopamine neurons. Further, THB also blocks pancreatic ?-cell KATP channels, and can be developed to a novel drugs for treating disease and/or conditions such as diabetes and Parkinson's disease.Type: ApplicationFiled: May 2, 2011Publication date: February 21, 2013Applicant: DIGNITY HEALTHInventor: Jie Wu